Chugai Pharmaceutical Co. Ltd: PharmaVitae Profile

Publication Date	August 2008
Publisher	Datamonitor
Product Type	Report
Pages	156
ISBN Number	not applicable
Product Code	DAT13070

Price

£3,010.00
approximately: $4,398 | €3,299

PDF

PRINT £3,045 ($4,449 | €3,337)

Order above formats by FAX

Summary

Introduction

This analysis examines the historical and forecast performance for Chugai in the prescription pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs. An interactive forecasting and analysis tool provides continually updated quantitative and qualitative information.

Reasons to Purchase

Benchmark Chugai's performance against key rivals in the prescription pharmaceutical sector
Evaluate the impact of Chugai's alliance with Roche, including forecast strong growth for the Avastin franchise in Japan
Assess the forecast performance of Actemra, the first monoclonal antibody product to be developed and successfully launched by a Japanese company

Content

CHAPTER 1 ABOUT THIS PROFILE
- Executive summary
- Quarterly news update
- Company introduction
- Company sales
- Company financials
- Key products and competitors
- Data sourcing
- Sales data
- Analyst consensus
CHAPTER 2 EXECUTIVE SUMMARY
- Key findings
- Prescription pharmaceutical sales performance, 200113
- Financial performance, 200113
- Chugai Pharmaceutical Co., Ltd.: PharmaVitae forecasts at a glance
- Strategic insight
- The Chugai-Roche alliance
- SWOT analysis
- Strengths
- Weaknesses
- Opportunities
- Threats
CHAPTER 3 QUARTERLY NEWS UPDATE
- Product developments
- Deals and alliances
- Product deals
- Technology deals
- M&A activity
- Company announcements
- Future product milestones
CHAPTER 4 COMPANY INTRODUCTION
- Key findings
- Background
- Key corporate developments
- M&A history
- 1) Acquisition of GenProbe December 1989
- 2) Consolidation into the Roche Group - October 2002
- 3) Divestments post Roche merger promote Rx focus
- Current corporate structure
- Pharmaceuticals business unit structure
CHAPTER 5 COMPANY SALES
- Key findings
- Prescription pharmaceutical sales and growth rate analysis, 200113
- Product analysis
- Product analysis, 200107
- Product analysis, 200713
- Therapy area analysis
- Therapy area analysis, 200107
- Therapy area analysis, 200713
- Therapy area focus, 200113
- Geographic analysis
- Geographic analysis, 200107
- Geographic analysis, 200713
- Geographic focus, 200113
- Launch/core/expiry analysis
- Launch analysis, 200713
- Core analysis, 200713
- Expiry analysis, 200713
- Launch/core/expiry configuration, 200713
- Molecule type analysis
- Molecule type analysis, 200107
- Molecule type analysis, 200713
- Externalization analysis
- Externalization analysis, 200107
- Externalization analysis, 200713
CHAPTER 6 COMPANY FINANCIALS
- Key findings
- Reconciliation between PharmaVitae-formatted prescription pharma sales and company-reported total sales, 200107
- Financial statements, 200107
- Profit and loss account, 200107
- Balance sheet, 200107
- Operating costs and profit analysis
- Operating costs and profit analysis, 200107
- Operating cost ratio and profit margin analysis, 200107
- Operating cost ratio and profit margin analysis, 200713
- Operating costs and profit analysis, 200713
CHAPTER 7 KEY PRODUCTS AND COMPETITORS
- Key findings
- Overview
- Oncology
- Avastin
- Herceptin
- Neutrogin
- Rituxan
- Tarceva
- Hematology
- Epogin
- R-744/Mircera
- Urology and sexual health
- Evista
- Immunology and Inflammation
- Actemra
- Musculoskeletal
- R-484/Boniva
- Infectious disease
- Pegasys
- Tamiflu
CHAPTER 8 APPENDIX
- R&D pipeline
- Market assumptions
- References Error! Bookmark not defined.
- Abbreviations
- Exchange rates
TABLE OF TABLES
- Table 1: Chugai Pharmaceutical Co., Ltd. PharmaVitae forecasts at a glance
- Table 2: Chugai Pharmaceutical Co., Ltd. key product developments, 2008
- Table 3: Chugai Pharmaceutical Co., Ltd. product deals and alliances, 2008
- Table 4: Chugai Pharmaceutical Co., Ltd. technology deals and alliances, 2008
- Table 5: Chugai Pharmaceutical Co., Ltd. M&A activity, 2008
- Table 6: Chugai Pharmaceutical Co., Ltd. company announcements, 2008
- Table 7: Chugai Pharmaceutical Co., Ltd. future product milestones, 200810
- Table 8: Chugai Pharmaceutical Co., Ltd. product portfolio overview ($m), 200107
- Table 9: Stockpiling vs. prescription Tamiflu sales ($m), 200307
- Table 10: Chugai Pharmaceutical Co., Ltd. product portfolio overview ($m), 200713
- Table 11: Chugai Pharmaceutical Co., Ltd. product portfolio overview ($m), 200107
- Table 12: Chugai Pharmaceutical Co., Ltd. product portfolio overview ($m), 200713
- Table 13: Chugai Pharmaceutical Co., Ltd. portfolio overview by geographic region ($m), 200107
- Table 14: Chugai Pharmaceutical Co., Ltd. portfolio overview by geographic region ($m), 200713
- Table 15: Chugai Pharmaceutical Co., Ltd. launch portfolio overview ($m), 200713
- Table 16: Chugai Pharmaceutical Co., Ltd. core portfolio overview ($m), 200713
- Table 17: Chugai Pharmaceutical Co., Ltd. expiry portfolio overview ($m), 200713
- Table 18: Chugai Pharmaceutical Co., Ltd. portfolio overview by molecule type ($m), 200107
- Table 19: Chugai Pharmaceutical Co., Ltd. product portfolio overview by molecule type ($m), 200713
- Table 20: Chugai Pharmaceutical Co., Ltd. product portfolio overview by source ($m), 200107
- Table 21: Chugai Pharmaceutical Co., Ltd. product portfolio overview by source ($m), 200713
- Table 22: Total Chugai Pharmaceutical Co., Ltd. sales by business unit ($m), 200107
- Table 23: Chugai Pharmaceutical Co., Ltd. profit and loss account ($m), 200107
- Table 24: Chugai Pharmaceutical Co., Ltd. balance sheet ($m), 200107
- Table 25: Chugai Pharmaceutical Co., Ltd. operating revenue/cost analysis ($m), 200107
- Table 26: Chugai Pharmaceutical Co., Ltd. operating cost ratio analysis (% of total revenues), 200107
- Table 27: Chugai Pharmaceutical Co., Ltd. operating cost ratio analysis (% of total revenues), 200713
- Table 28: Chugai Pharmaceutical Co., Ltd. operating revenue/cost analysis ($m), 200713
- Table 34: Key products overview
- Table 35: Avastin: overview
- Table 36: Avastin: sales forecast ($m), 200713
- Table 37: Herceptin: overview
- Table 38: Herceptin: sales forecast ($m), 200713
- Table 39: Neutrogin: overview
- Table 40: Neutrogin: sales forecast ($m), 200713
- Table 41: Rituxan: overview
- Table 42: Rituxan: sales forecast ($m), 200713
- Table 43: Tarceva: overview
- Table 44: Tarceva: sales forecast ($m), 200713
- Table 45: Epogin: overview
- Table 46: Epogin: sales forecast ($m), 200713
- Table 47: R-744/Mircera: overview
- Table 48: R-744/Mircera: sales forecast ($m), 200713
- Table 49: Evista: overview
- Table 50: Evista: sales forecast ($m), 200713
- Table 51: Actemra: overview
- Table 52: Actemra: sales forecast ($m), 200713
- Table 53: R-484/Boniva: overview
- Table 54: R-484/Boniva: sales forecast ($m), 200713
- Table 55: Pegasys: overview
- Table 56: Pegasys: sales forecast ($m), 200713
- Table 57: Tamiflu: overview
- Table 58: Tamiflu: sales forecast ($m), 200713
- Table 59: Stockpiling vs. prescription Tamiflu sales ($m), 200307
- Table 60: Chugai Pharmaceutical Co., Ltd.s R&D pipeline (Phase Iregistration)
- Table 61: Chugai Pharmaceutical Co., Ltd.s indication broadening pipeline (Phase Iregistration)
- Table 62: Exchange rates, 2007
TABLE OF FIGURES
- Figure1: Chugai Pharmaceutical Co., Ltd. prescription pharmaceutical performance, sales ($m) and growth rate (%), 200113
- Figure2: Chugai Pharmaceutical Co., Ltd.s financial performance ($m), 200113
- Figure3: Source of mAb portfolio
- Figure4: Chugai Pharmaceutical Co., Ltd. sales by company source ($m), 200113
- Figure5: Chugai Pharmaceutical Co., Ltd. growth drivers by company source ($m), 200713
- Figure6: Chugai Pharmaceutical Co., Ltd. SWOT analysis
- Figure5: Current corporate structure
- Figure6: Chugai business unit structure, 200107
- Figure7: Chugai Pharmaceutical Co., Ltd. prescription pharmaceutical performance, sales ($m) and growth rate (%), 200113
- Figure8: Chugai Pharmaceutical Co., Ltd. key sales growth driver & resistors ($m), 200107
- Figure9: Chugai Pharmaceutical Co., Ltd. key sales growth drivers & resistors ($m), 200713
- Figure10: Chugai Pharmaceutical Co., Ltd. prescription pharmaceutical sales by therapy area ($m), 200113
- Figure11: Chugai Pharmaceutical Co., Ltd. prescription pharma sales by therapy area (% of total), 200113
- Figure12: Chugai Pharmaceutical Co., Ltd. prescription pharmaceutical sales by geographic region ($m), 200113
- Figure13: Chugai Pharmaceutical Co., Ltd. growth drivers and resistors by geographic region ($m), 200107
- Figure14: Chugai Pharmaceutical Co., Ltd. drivers and resistors by geographic region ($m), 200713
- Figure15: Chugai Pharmaceutical Co., Ltd. prescription pharmaceutical sales by geographic region (% of total), 200113
- Figure16: Chugai Pharmaceutical Co., Ltd. launch/core/expiry configuration ($m), 200713
- Figure17: Chugai Pharmaceutical Co., Ltd. prescription pharmaceutical sales by molecule type ($m), 200113
- Figure18: Chugai Pharmaceutical Co., Ltd. growth drivers and resistors by molecule type ($m), 200713
- Figure19: Chugai Pharmaceutical Co., Ltd. prescription pharmaceutical sales by source ($m), 200113
- Figure20: Chugai Pharmaceutical Co., Ltd. growth drivers and resistors by source ($m), 200107
- Figure21: Chugai Pharmaceutical Co., Ltd. growth drivers and resistors by source ($m), 200713
- Figure22: Chugai Pharmaceutical Co., Ltd. operating revenue/cost analysis ($m), 200113
- Figure23: Chugai Pharmaceutical Co., Ltd. operating cost ratio analysis (% of total revenues), 200113